Summary
A placebo-controlled double blind study is reported of a nine-week trial of mepazine in fixed daily dosage of 300 mg on a hospitalized population of 60 male chronic schizophrenic patients, the majority already receiving another phenothiazine.
There was no statistically significant difference between drug and placebo group for any of 8 measures employed, including two psychological tests selected to describe aspects of intellection. On four impressional measures there were more patients in the drug group than in the placebo group who improved, or who evidenced less somatic symptoms; however, statistical treatment of the data describing these differences showed no variation beyond chance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bowes, A.: The ataractic drugs, the present position of chlorpromazine, Frenquel, Pacatal and Reserpine in the Psychiatric Hospital. Extracted from the paper read to the American Psychiatric Association in Chicago on May 4, 1956. Amer. J. Psychiat. 113, 530 (1956).
Braun, M.: Pacatal. Amer. J. Psychiat. 113, 838 (1957).
Bruckman, N., M. Kitchener, J. C. Saunders and N. S. Kline: Mepazine (Pacatal) — Further Report. Amer. J. Psychiat. 114 (3), 262–263 (1957).
Denber, H. C. B.: Ineffectiveness of Mepazine (Pacatal). Amer. J. Psychiat. 114 (7), 656 (1958).
Epstein, S.: Overinclusive thinking in a schizophrenic and a control group. J. cons. Psychol. 17, 184–388 (1953).
Feldman, P. E.: Clinical evaluation of Pacatal. Amer. J. Psychiat. 114 (2), 143–146 (1957).
Flipse, M. J.: Pacatal in office practice: An evaluation of a new phenothiazine derivative in a series of 50 out-patients suffering from varying degrees of emotional disturbances. Clin. Med. 4 (10), 1237, 1239–1241 (1957).
Friedgood, C. E.: The use of Pacatal in a variety of clinical entities. Scientific exhibit presented at New York State Society of Medicine meeting February 18, 1957.
Hiob, J., u. H. Hippius: Über die Behandlung von Psychosen mit dem Phenothiazin-Derivat „Pacatal“. Med. Klin. 50, 1746–1748 (1955).
Hutchinson, J. T.: Evaluation of Pacatal in psychotic states. Abstract of paper read to the American Psychiatric Association at the University of Pennsylvania in Philadelphia on November 16, 1956.
Kautz, H. D.: Council on Drugs — report on Mepazine acetate (Mepazine hydrochloride). J. Amer. med. Ass. 167, 1632–1633 (1958).
Kline, N. S., and G. M. Jacob: Use of Pacatal (N-methylpiperidyl-(3)-methylphenothiazine) in psychiatric patients. Amer. J. Psychiat. 112 (1), 63 (1955).
MacGregor, J. Macw.: “Pacatal” — A clinical trial of a new ataractic drug. S. Afr. med. J. 30 (46), 1108–1111 (1956).
Sarwer-Foner, G. J., and E. K. Koranyi: The clinical investigation of Pacatal in open psychiatric settings. Canad. med. Ass. J. 77, 450–459 (1957).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Whittier, J.R., Klein, D.F., Levine, G. et al. Mepazine (pacatal): Clinical trial with placebo control and psychological study. Psychopharmacologia 1, 280–287 (1960). https://doi.org/10.1007/BF00404225
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00404225